Sun Pharma plunges 10% as SEBI plans to reopen insider trading case

Sun Pharma plunges 10% as SEBI plans to reopen insider trading case Sun Pharma, along with its Managing Director Dilip Shanghvi, and nine others had settled the insider trading probe, paying Rs 18 lakh against the settlement charges in 2017

No comments:

Post a Comment